The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinsons disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinsons disease.